Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Study Details
Study Description
Brief Summary
The purpose of this study is to demonstrate the utility of measuring outcomes in 5% treatment naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) patients using infusion nurse and patient measured physical, quality of life (QOL), respiratory, and disability assessments using CareExchange in the home setting.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Gammaplex® IVIg
|
Outcome Measures
Primary Outcome Measures
- Analysis of collected data captured in CareExchange will demonstrate the ability to show and track changes in outcome data in 5% treatment naïve IVIg PIDD patients in the home setting. [1 year]
Secondary Outcome Measures
- Evaluate the profile physician usage (dose and timing) with Gammaplex®. [1 year]
- Evaluate physician feedback to having real-time access to 5% treatment naïve IVIg PIDD data captured during home infusions. [1 year]
- Evaluate the safety profile of using a 5% treatment naïve IVIg in PIDD patients in the home setting. [1 year]
- Demonstration of response rate for those receiving IVIg therapies. [1 year]
- Demonstration of changes in outcomes as a result of changes made in IVIg dose and frequency during study participation. [1 year]
- Demonstration of measured variables within patients who receive IVIg therapies. [1 year]
- Evaluate the effectiveness of whether CareExchange leads to better QOLs and overall patient reported outcomes. [1 year]
- Other potential impacts on change in outcomes across patient demographics (age, sex, race, ethnicity, etc.). [1 year]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosis of any form of Primary Immunodeficiency Disease
-
Males and Females
-
≥ 15 and ≤ 85 years of age
-
5% treatment Naïve IVIg for the treatment of PIDD
-
Ability to have Gammaplex® IVIg prescribed under the discretion of the patient's treating physician in accordance with standard treatment practices for the entire duration of the study
-
Ability and willingness to provide informed consent and comply with study requirements and procedures
-
Ability to read and write English
-
Understanding of study procedures and ability to comply with study procedures for the entire length of the study
-
Eligible for infusion services by AxelaCare Health Solutions, LLC, in collaboration with the subject's prescribing physician and insurance provider
Exclusion Criteria:
-
The presence of any medical condition that the investigator and/or prescribing physician deems incompatible with participation in this trial.
-
Prisoners, and other wards of the state
-
Determined to have non-competency of data collection requirements (physical assessments and use of an iPAD™) by either the home infusion nurse and/or Caregiver.
-
Receiving Subcutaneous Immunoglobulin (SCIg) Therapy during study participation.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hoag Medical Group (In Alliance with St. Joseph Heritage Healthcare) | Newport Beach | California | United States | 92663 |
| 2 | IMMUNEOe International Research Centers | Centennial | Colorado | United States | 80122 |
| 3 | Atlanta ENT | Atlanta | Georgia | United States | 30342 |
| 4 | AxelaCare Health Solutions, LLC | Lenexa | Kansas | United States | 66219 |
Sponsors and Collaborators
- BriovaRx Infusion Services
- Bio Products Laboratory (BPL)
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AHS1-13-003